Theorem Clinical Research

R&D Trends

Tute Genomics, Google Genomics collaborate on genetic database

Thursday, March 19, 2015 12:03 PM

Tute Genomics, a Utah­-based provider of a clinical genome interpretation platform, along with Dr. Xiaoming Liu and his team at the University of Texas, have teamed up with Google to grant public access to a database of 8.5 billion annotations of genetic variants through Google Genomics.

More... »

Quest Diagnostics

Qiagen, Tokai Pharmaceuticals partner

Wednesday, March 18, 2015 01:18 PM

Qiagen, a Netherlands-based holding company, has partnered with Germany-based Tokai Pharmaceuticals to combine new circulating tumor cells (CTCs) technology with a molecular assay to co-develop and commercialize a companion diagnostic for Tokai's novel drug compound galeterone, which is in late-stage clinical trials for treatment of castration-resistant prostate cancer (CRPC). The non-invasive test will determine the expression of the AR-V7 biomarker, which in recent studies demonstrated potential utility to guide therapy choice in CRPC patients.

More... »


NantWorks, Sorrento collaborate on novel anti-cancer immunotherapies

Wednesday, March 18, 2015 01:16 PM

NantWorks, an umbrella organization developing of next generation diagnostics and therapeutics, and Sorrento Therapeutics, an oncology company, have entered into a binding agreement to initiate a global collaboration to discover and develop novel anti-cancer immunotherapies derived from Sorrento's proprietary G-MAB library against neoepitopes of tumor-specific antigens discovered using NantWorks' proprietary pan-omics based, precision medicine approach.

More... »

$100M invested in new Dementia Discovery fund

Wednesday, March 18, 2015 01:11 PM

The U.K. government has announced over $100 million will be invested in a pioneering new global Dementia Discovery Fund. Major pharmaceutical companies Biogen Idec, GlaxoSmithKline, Johnson & JohnsonEli Lilly and Pfizer have all committed in principle to investing in the project, alongside Alzheimer's Research U.K. and the U.K. government.

More... »

Cloud Pharmaceuticals, University of Florida collaborate

Wednesday, March 18, 2015 01:09 PM

Cloud Pharmaceuticals, a Research Triangle Park, N.C.-based therapeutics company focused on cloud-based drug design and development, and the University of Florida’s department of medicine have announced an academic collaboration to help rapidly design and develop novel drugs to inhibit the reproduction of cancer cells.

More... »

Study: How much should cancer drugs cost?

Monday, March 16, 2015 01:54 PM

The true cost of cancer drugs is 30% less than a decade ago, once longevity and quality of life are considered, according to a Cornell University researchers based on a study, A Quality-Adjusted Price Index for Colorectal Cancer Drugs, released by the National Bureau of Economic Research (NBER).

More... »

New immunotechnology center MI-mAbs launched

Monday, March 16, 2015 01:48 PM

MI-mAbs, a new immunotechnology center designed to accelerate the development of new immunotherapy antibodies against cancer and inflammatory disease and founding member of the France-based Marseille Immunopole (MI) cluster, has announced the signature of the consortium agreement sealing the commitment of its founders: Aix-Marseille Universite (AMU) and its private subsidiary Protisvalor, CNRS, Inserm, the Institute Paoli-Calmettes (IPC); three of their research centers (the Centre d'Immunologie de Marseille-Luminy, the Cancer Research Center of Marseille and the Center for Immunophenomics); Innate Pharma, a European immuno-oncology company; and Sanofi.

More... »

Second Genome, Evotec to collaborate in microbiome discovery and development

Monday, March 16, 2015 01:47 PM

Evotec, a drug discovery alliance and development partnership company based in Germany, and Second Genome, a South San Francisco-based therapeutic developer, are collaborating on small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases.

More... »

Report: Declining Ebola cases pose serious challenge to clinical studies

Thursday, March 12, 2015 01:01 PM

The steady decline in new Ebola cases presents a formidable challenge to current and future clinical trials of investigational treatments for the disease, as it will be more difficult to recruit study participants and demonstrate efficacy, said an analyst with research and consulting firm GlobalData.

More... »

Report: U.S. prescription drug spending increased 13.1% in 2014

Thursday, March 12, 2015 12:56 PM

New hepatitis C therapies with high price tags and the exploitation of loopholes for compounded medications drove a 13.1% increase in U.S. drug spending in 2014—a rate not seen in more than a decade—according to new data released in the 2014 Express Scripts Drug Trend Report. Headquartered in St. Louis, Mo., Express Scripts provides integrated pharmacy-benefit management services.

More... »

AiCure
CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs